Efficacy, safety and regulatory status of SGLT2 inhibitors: Focus on canagliflozin

Nutrition and Diabetes

Volumn 4, Issue 11, 2014, Pages

  Haas, B ^a   Eckstein, N ^a,b   Pfeifer, V ^a   Mayer, P ^a   Hass, M D S ^a  

^a FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES KAISERSLAUTERN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; GLUCOSE;

ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE URINE LEVEL; GLYCEMIC CONTROL; HUMAN; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REGULATORY MECHANISM; TISSUE DISTRIBUTION; URINARY TRACT INFECTION;

EID: 84927744959     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2014.40     Document Type: Article

References (52)

1. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346.
2. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 3-19.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
4. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298.
5. Liday C. Overview of the guidelines and evidence for the pharmacologic management of type 2 diabetes mellitus. Pharmacotherapy 2011; 31(12 Suppl): 37S-43S.
6. Ferrannini E. The target of metformin in type 2 diabetes. N N Engl J Med 2014; 371: 1547-1548.
7. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
8. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-754.
9. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206.
10. Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209.
11. Mitka M. More patients get good diabetes control, but only a minority meet all goals. JAMA 2013; 309: 1335-1336.
12. Lawrence DB, Ragucci KR, Long LB, Parris BS, Helfer LA. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm 2006; 12: 466-471.
13. Chao EC, Henry RR. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010; 9: 551-559.
14. Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl 2011; 120: S1-S6.
15. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010; 27: 136-142.
16. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261: 32-43.
17. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733-794.
18. Barfuss DW, Schafer JA. Differences in active and passive glucose transport along the proximal nephron. Am J Physiol 1981; 241: F322-F332.
19. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951; 30: 125-129.
20. Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol 2012; 52: 457-463.
21. Burki TK. FDA rejects novel diabetes drug over safety fears. Lancet 2012; 379: 507.
22. European Medicins Agency [http://www.ema.europa.eu/ema/]. 2014.
23. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159: 262-274.
24. Yale JF, Bakris G, Cariou B, Nieto J, Wajs E, Figueroa K et al. Efficacy and Safety of Canagliflozin (CANA) in Subjects with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) Over 52 Weeks. Can J Diabetes 2013; 37(Suppl 4): S27.
25. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44: 375-393.
26. Committee for Medicinal Products for Human Use. European Public Assessment Report (EPAR) Canagliflozin. European Medicines Agency 2013. EMA/374133/2013.
27. Luippold G, Klein T, Mark M, Grempler R. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes Metab 2012; 14: 601-607.
28. Lamos EM, Younk LM, Davis SN. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Invest Drugs 2014; 23: 875-882.
29. Bode B, Stenlof K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995) 2013; 41: 72-84.
30. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950.
31. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8: 262-275.
32. Calado J, Sznajer Y, Metzger D, Rita A, Hogan MC, Kattamis A et al. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant 2008; 23: 3874-3879.
33. Nicolle LE, Capuano G, Fung A, Usiskin K. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med 2014; 126: 7-17.
34. Elmore LK, Baggett S, Kyle JA, Skelley JW. A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes. Consult Pharm 2014; 29: 335-346.
35. Sinclair A, Bode B, Harris S, Vijapurkar U, Mayer C, Fung A et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord 2014; 14: 37.
36. De NL, Gabbai FB, Liberti ME, Sagliocca A, Conte G, Minutolo R. Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes. Am J Kidney Dis 2014; 64: 16-24.
37. Committee for Medicinal Products for Human Use. European Public Assessment Report (EPAR) Dapagliflozin. European Medicines Agency 2012. EMA/689976/2012.
38. Reilly TP, Graziano MJ, Janovitz EB, Dorr TE, Fairchild C, Lee F et al. Carcinogenicity risk assessment upports the chronic Ssfety of dapagliflozin, an inhibitor of sodium-slucose co-transporter 2, in the reatment of type 2 diabetes mellitus. Diabetes Ther 2014; 5: 73-96.
39. Neal B, Perkovic V, de ZD, Mahaffey KW, Fulcher G, Stein P et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. Am Heart J 2013; 166: 217-223.
40. Tazawa S, Yamato T, Fujikura H, Hiratochi M, Itoh F, Tomae M et al. SLC5A9/SGLT4, a new Na+ dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci 2005; 76: 1039-1050.
41. Diez-Sampedro A, Wright EM, Hirayama BA. Residue 457 controls sugar binding and transport in the Na(+)/glucose cotransporter. J Biol Chem 2001; 276: 49188-49194.
42. Kothinti RK, Blodgett AB, North PE, Roman RJ, Tabatabai NM. A novel SGLT is expressed in the human kidney. Eur J Pharmacol 2012; 690: 77-83.
43. Aouameur R, Da CS, Bissonnette P, Coady MJ, Lapointe JY. SMIT2 mediates all myo-inositol uptake in apical membranes of rat small intestine. Am J Physiol Gastrointest Liver Physiol 2007; 293: G1300-G1307.
44. Diez-Sampedro A, Lostao MP, Wright EM, Hirayama BA. Glycoside binding and translocation in Na(+) dependent glucose cotransporters: comparison of SGLT1 and SGLT3. J Membr Biol 2000; 176: 111-117.
45. Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 2011; 300: C14-C21.
46. Hager K, Hazama A, Kwon HM, Loo DD, Handler JS, Wright EM. Kinetics and specificity of the renal Na+/myo-inositol cotransporter expressed in Xenopus oocytes. J Membr Biol 1995; 143: 103-113.
47. Voss AA, Diez-Sampedro A, Hirayama BA, Loo DD, Wright EM. Imino sugars are potent agonists of the human glucose sensor SGLT3. Mol Pharmacol 2007; 71: 628-634.
48. US Food and Drug Administaration [http://www.fda.gov/]. 2014.
49. Pharmaceuticals and Medical Devices Agency, Japan [http://www.pmda.go.jp/]. 2014.
50. Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372-382.
51. Stenlof K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014; 30: 163-175.
52. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36: 2508-2515.